[Primary safety analysis of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients]
| Autor: | Ning-Ning, Zhou, Xiao-Yu, Teng, Dong-Geng, Liu, Ran, Xu, Zhong-Zhen, Guan |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Fever Receptor ErbB-2 Carcinoma Ductal Breast Shivering Antibodies Monoclonal Antineoplastic Agents Breast Neoplasms Stroke Volume Middle Aged Trastuzumab Antibodies Monoclonal Humanized Chemotherapy Adjuvant Heart Function Tests Humans Female Postoperative Period Mastectomy Aged Retrospective Studies |
| Zdroj: | Ai zheng = Aizheng = Chinese journal of cancer. 27(12) |
| Popis: | It has been proved that trastuzumab has clinical activity in early and advanced breast cancer with Her2-overexpression. This study was to analyze the safety of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients.Trastuzumab was administrated after adjuvant chemotherapy every 21 days. The initial dose was 8 mg/kg, and the subsequent dose was 6 mg/kg, for four to 35 cycles (medium 18 cycles). The side effects of these patients, especially cardiotoxicity, were analyzed.Thirty patients with Her2-positive early breast cancer were entered into the study. The average treatment period was one year (range nine weeks to two years). Two patients had shivering and fever during the first infusion with trastuzumab. Left ventricular ejection fraction (LVEF) level dropped in 18 cases after treatment with trastuzumab, half of which decreased more then 10%û however, no cardiac failure was observed.The post-surgical treatment of trastuzumab in Chinese patients with Her2-positive early breast cancer shows a satisfactory safety profile. However, the potential cardiotoxicity of trastuzumab should be carefully monitored during therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|